iTeos Therapeutics (NASDAQ:ITOS) Shares Gap Up to $15.73

Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) gapped up prior to trading on Monday . The stock had previously closed at $15.73, but opened at $16.33. iTeos Therapeutics shares last traded at $15.92, with a volume of 2,603 shares.

Analysts Set New Price Targets

A number of brokerages have issued reports on ITOS. Wedbush reissued an “outperform” rating and set a $21.00 price objective on shares of iTeos Therapeutics in a research report on Monday, June 17th. HC Wainwright increased their price target on shares of iTeos Therapeutics from $44.00 to $46.00 and gave the stock a “buy” rating in a research note on Monday, May 13th.

iTeos Therapeutics Price Performance

The firm has a market cap of $592.78 million, a PE ratio of -4.34 and a beta of 1.40. The firm has a 50-day simple moving average of $16.20 and a 200 day simple moving average of $13.10.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Friday, May 10th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.05). Sell-side analysts forecast that iTeos Therapeutics, Inc. will post -4.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On iTeos Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ITOS. Federated Hermes Inc. boosted its position in shares of iTeos Therapeutics by 4,648.4% in the 4th quarter. Federated Hermes Inc. now owns 2,944 shares of the company’s stock worth $32,000 after purchasing an additional 2,882 shares in the last quarter. Gladius Capital Management LP grew its stake in shares of iTeos Therapeutics by 48.7% in the fourth quarter. Gladius Capital Management LP now owns 3,131 shares of the company’s stock worth $34,000 after acquiring an additional 1,026 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of iTeos Therapeutics by 348.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,140 shares of the company’s stock valued at $45,000 after acquiring an additional 3,216 shares in the last quarter. Signaturefd LLC increased its holdings in shares of iTeos Therapeutics by 268.5% during the fourth quarter. Signaturefd LLC now owns 4,481 shares of the company’s stock valued at $49,000 after acquiring an additional 3,265 shares in the last quarter. Finally, AJOVista LLC purchased a new position in shares of iTeos Therapeutics in the 4th quarter worth about $57,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.